Prostaglandin E2 and T cells: friends or foes?

[1]  C. Jean,et al.  PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. , 2010, Biochemical pharmacology.

[2]  B. Samuelsson,et al.  Microsomal prostaglandin E synthase‐1 and 5‐lipoxygenase: potential drug targets in cancer , 2010, Journal of internal medicine.

[3]  S. Narumiya,et al.  Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis , 2010, Proceedings of the National Academy of Sciences.

[4]  A. Chakraborti,et al.  Progress in COX-2 inhibitors: a journey so far. , 2010, Current medicinal chemistry.

[5]  T. Sumida,et al.  A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models , 2010, British journal of pharmacology.

[6]  S. Narumiya,et al.  Prostaglandin E2, an immunoactivator. , 2010, Journal of pharmacological sciences.

[7]  F. Chan,et al.  Nonsteroid anti-inflammatory drug-induced gastroduodenal injury , 2009, Current opinion in gastroenterology.

[8]  O. Werz,et al.  Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs)--a critical review. , 2009, Current medicinal chemistry.

[9]  S. Ostrand-Rosenberg,et al.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function , 2009, Breast Cancer Research and Treatment.

[10]  S. Narumiya,et al.  Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion , 2009, Nature Medicine.

[11]  M. Schubert-Zsilavecz,et al.  Nonsteroidal anti-inflammatory drugs: a critical review on current concepts applied to reduce gastrointestinal toxicity. , 2009, Current medicinal chemistry.

[12]  F. Sallusto,et al.  Prostaglandin E2 enhances Th17 responses via modulation of IL‐17 and IFN‐γ production by memory CD4+ T cells , 2009, European journal of immunology.

[13]  T. Mcclanahan,et al.  Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling , 2009, The Journal of experimental medicine.

[14]  P. Krause,et al.  Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. , 2009, Blood.

[15]  Heather R. Roberts,et al.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. , 2009, Carcinogenesis.

[16]  J. Dayer,et al.  Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. , 2008, Blood.

[17]  M. Ahmadi,et al.  Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. , 2008, Cancer research.

[18]  K. Krishnaswamy,et al.  A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[19]  D. Bartlett,et al.  Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. , 2008, Cancer research.

[20]  D. Ganea,et al.  In Vitro Differentiation of Dendritic Cells in the Presence of Prostaglandin E2 Alters the IL-12/IL-23 Balance and Promotes Differentiation of Th17 Cells1 , 2008, The Journal of Immunology.

[21]  E. Aandahl,et al.  LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. , 2008, International immunology.

[22]  R. Flower,et al.  Treatment of inflammatory diseases by selective eicosanoid inhibition: a double-edged sword? , 2007, Trends in pharmacological sciences.

[23]  Ralf Morgenstern,et al.  Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target , 2007, Pharmacological Reviews.

[24]  D. Nie,et al.  Cyclooxygenases, prostanoids, and tumor progression , 2007, Cancer and Metastasis Reviews.

[25]  C. Mody,et al.  Elevated expression of prostaglandin receptor and increased release of prostaglandin E2 maintain the survival of CD45RO+ T cells in the inflamed human pleural space , 2007, Immunology.

[26]  S. Narumiya,et al.  Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.

[27]  C. Woolf,et al.  Prostaglandin E2 Receptor EP4 Contributes to Inflammatory Pain Hypersensitivity , 2006, Journal of Pharmacology and Experimental Therapeutics.

[28]  Á. Lanas,et al.  Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. , 2006, Prostaglandins & other lipid mediators.

[29]  M. Lejeune,et al.  Prostaglandin E2 receptor distribution and function in the gastrointestinal tract , 2006, British journal of pharmacology.

[30]  J. Calixto,et al.  Pharmacological and Molecular Characterization of the Mechanisms Involved in Prostaglandin E2-Induced Mouse Paw Edema , 2006, Journal of Pharmacology and Experimental Therapeutics.

[31]  C. Figdor,et al.  A Critical Role for Prostaglandin E2 in Podosome Dissolution and Induction of High-Speed Migration during Dendritic Cell Maturation1 , 2006, The Journal of Immunology.

[32]  E. Aandahl,et al.  FOXP3+CD4+CD25+ Adaptive Regulatory T Cells Express Cyclooxygenase-2 and Suppress Effector T Cells by a Prostaglandin E2-Dependent Mechanism1 , 2006, The Journal of Immunology.

[33]  J. Redondo,et al.  Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. , 2006, Cardiovascular research.

[34]  Xinrong Ma,et al.  Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. , 2006, Cancer research.

[35]  P. Krause,et al.  Prostaglandin E2 Is Generally Required for Human Dendritic Cell Migration and Exerts Its Effect via EP2 and EP4 Receptors1 , 2006, The Journal of Immunology.

[36]  T. Zander,et al.  Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. , 2006, Cancer research.

[37]  J. Regan,et al.  EP4 Prostanoid Receptor Coupling to a Pertussis Toxin-Sensitive Inhibitory G Protein , 2006, Molecular Pharmacology.

[38]  M. Sykes,et al.  Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs. , 2005, International immunology.

[39]  Li Zhu,et al.  Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells1 , 2005, The Journal of Immunology.

[40]  M. Huang,et al.  Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.

[41]  G. Piraino,et al.  Prostaglandin E2 Induces Interleukin-8 Gene Transcription by Activating C/EBP Homologous Protein in Human T Lymphocytes* , 2005, Journal of Biological Chemistry.

[42]  Leslie J Crofford,et al.  Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2 , 2005, Arthritis research & therapy.

[43]  E. Hooghe-Peters,et al.  Mechanism of Prostaglandin (PG)E2-Induced Prolactin Expression in Human T Cells: Cooperation of Two PGE2 Receptor Subtypes, E-Prostanoid (EP) 3 and EP4, Via Calcium- and Cyclic Adenosine 5′-Monophosphate-Mediated Signaling Pathways1 , 2004, The Journal of Immunology.

[44]  R. Botting,et al.  Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition , 2004, Pharmacological Reviews.

[45]  D. Ganea,et al.  Prostaglandin E2 induces IL‐23 production in bone marrow‐derived dendritic cells , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  Nunzio Bottini,et al.  Haematopoietic protein tyrosine phosphatase (HePTP) phosphorylation by cAMP-dependent protein kinase in T-cells: dynamics and subcellular location. , 2004, The Biochemical journal.

[47]  M. Berridge,et al.  Calcium: Calcium signalling: dynamics, homeostasis and remodelling , 2003, Nature Reviews Molecular Cell Biology.

[48]  K. Taskén,et al.  Combined Spatial and Enzymatic Regulation of Csk by cAMP and Protein Kinase A Inhibits T Cell Receptor Signaling* , 2003, The Journal of Biological Chemistry.

[49]  J. Regan,et al.  Prostaglandin E2 Induced Functional Expression of Early Growth Response Factor-1 by EP4, but Not EP2, Prostanoid Receptors via the Phosphatidylinositol 3-Kinase and Extracellular Signal-regulated Kinases* , 2003, The Journal of Biological Chemistry.

[50]  J. Redondo,et al.  Cyclooxygenase-2: a therapeutic target in angiogenesis. , 2003, Trends in molecular medicine.

[51]  T. Lawrence,et al.  Anti-inflammatory lipid mediators and insights into the resolution of inflammation , 2002, Nature Reviews Immunology.

[52]  S. Mineishi,et al.  The Role of PGE2 in the Differentiation of Dendritic Cells: How Do Dendritic Cells Influence T‐Cell Polarization and Chemokine Receptor Expression? , 2002, Stem cells.

[53]  E. Palmer,et al.  The T-cell receptor signalosome: a dynamic structure with expanding complexity. , 2002, Current opinion in immunology.

[54]  R. Phipps,et al.  Prostaglandins as modulators of immunity. , 2002, Trends in immunology.

[55]  J. Regan,et al.  Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 * , 2002, The Journal of Biological Chemistry.

[56]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[57]  B. Koller,et al.  Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. , 2001, The Journal of clinical investigation.

[58]  F. Cipollone,et al.  Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.

[59]  B. Koller,et al.  Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. , 2001, The Journal of clinical investigation.

[60]  B. Ashby,et al.  Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. , 2000, Molecular pharmacology.

[61]  Y. Sugimoto,et al.  Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors. , 2000, Japanese journal of pharmacology.

[62]  Karel Drbal,et al.  Phosphoprotein Associated with Glycosphingolipid-Enriched Microdomains (Pag), a Novel Ubiquitously Expressed Transmembrane Adaptor Protein, Binds the Protein Tyrosine Kinase Csk and Is Involved in Regulation of T Cell Activation , 2000, The Journal of experimental medicine.

[63]  Toshifumi Takao,et al.  Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases , 2000, Nature.

[64]  I. Chaudry,et al.  Role of protein kinase C in cyclic AMP-mediated suppression of T-lymphocyte activation following burn injury. , 1999, Biochimica et biophysica acta.

[65]  M. Choudhry,et al.  PGE(2)-mediated inhibition of T cell p59(fyn) is independent of cAMP. , 1999, The American journal of physiology.

[66]  M. Fresno,et al.  Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. , 1999, Journal of immunology.

[67]  B. Samuelsson,et al.  Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[68]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[69]  M. Bastepe,et al.  Identification of a region of the C‐terminal domain involved in short‐term desensitization of the prostaglandin EP4 receptor , 1999, British journal of pharmacology.

[70]  R. Seder,et al.  Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. , 1998, Journal of immunology.

[71]  S. Uddin,et al.  Prostaglandin E2 modulation of p59fyn tyrosine kinase in T lymphocytes during sepsis. , 1998, Journal of immunology.

[72]  G. Delespesse,et al.  Prostaglandin E2 primes naive T cells for the production of anti‐inflammatory cytokines , 1997, European journal of immunology.

[73]  H. Katoh,et al.  Prostaglandin E Receptor EP3 Subtype Induces Neurite Retraction via Small GTPase Rho* , 1996, The Journal of Biological Chemistry.

[74]  A. Ichikawa,et al.  Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. , 1996, Molecular pharmacology.

[75]  F. Paliogianni,et al.  Prostaglandin E2 inhibits the nuclear transcription of the human interleukin 2, but not the Il-4, gene in human T cells by targeting transcription factors AP-1 and NF-AT. , 1996, Cellular immunology.

[76]  K. Arai,et al.  Signal transduction in Th clones: target of differential modulation by PGE2 may reside downstream of the PKC-dependent pathway. , 1996, Cytokine.

[77]  H. Jacobson,et al.  Differential localization of prostaglandin E receptor subtypes in human kidney. , 1996, The American journal of physiology.

[78]  C. Whitehurst,et al.  MEK1 and the extracellular signal-regulated kinases are required for the stimulation of IL-2 gene transcription in T cells. , 1996, Journal of immunology.

[79]  M. Choudhry,et al.  Role of Ca2+ in prostaglandin E2-induced T-lymphocyte proliferative suppression in sepsis , 1995, Infection and Immunity.

[80]  S. Corradin,et al.  Effect of PGE2 and of agents that raise cAMP levels on macrophage activation induced by IFN‐γ and TNF‐α , 1995, Journal of leukocyte biology.

[81]  T. Roszman,et al.  Induction of cAMP-dependent protein kinase (PKA) activity in T cells after stimulation of the prostaglandin E2 or the beta-adrenergic receptors: relationship between PKA activity and inhibition of anti-CD3 monoclonal antibody-induced T cell proliferation. , 1994, Cellular immunology.

[82]  R. Shigemoto,et al.  Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney. , 1994, The American journal of physiology.

[83]  H. Yssel,et al.  Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production. , 1994, International immunology.

[84]  R. Kincaid,et al.  Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways , 1993, The Journal of experimental medicine.

[85]  Y. Sugimoto,et al.  Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. , 1993, European journal of biochemistry.

[86]  P. Kalinski,et al.  Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. , 1993, Journal of immunology.

[87]  Y. Sugimoto,et al.  Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization. , 1993, The Journal of biological chemistry.

[88]  Y. Sugimoto,et al.  Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. , 1993, The Journal of biological chemistry.

[89]  F. Paliogianni,et al.  Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. , 1992, Journal of immunology.

[90]  J. Goodwin,et al.  Are prostaglandins proinflammatory, antiinflammatory, both or neither? , 1991, The Journal of rheumatology. Supplement.

[91]  M. Betz,et al.  Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. , 1991, Journal of immunology.

[92]  G. Dupuis,et al.  Effects of modulators of adenylyl cyclase on interleukin-2 production, cytosolic Ca2+ elevation, and K+ channel activity in Jurkat T cells. , 1990, Cellular immunology.

[93]  W. K. Sonnenburg,et al.  A prostaglandin E receptor coupled to a pertussis toxin-sensitive guanine nucleotide regulatory protein in rabbit cortical collecting tubule cells. , 1990, The Journal of biological chemistry.

[94]  Michael J. Berridge,et al.  Inositol phosphates and cell signalling , 1989, Nature.

[95]  A. López-Rivas,et al.  Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells , 1988, European journal of immunology.

[96]  R. Miller,et al.  Cyclic AMP concentrations modulate both calcium flux and hydrolysis of phosphatidylinositol phosphates in mouse T lymphocytes. , 1988, Journal of immunology.

[97]  J. Cleveland,et al.  Effects of anti-proliferative cyclic AMP on interleukin 2-stimulated gene expression. , 1987, Journal of immunology.

[98]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.

[99]  B. Ferruà,et al.  Regulation of interleukin 2 synthesis by cAMP in human T cells. , 1987, Journal of immunology.

[100]  K. Welte,et al.  Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate. , 1987, The Journal of clinical investigation.

[101]  P. J. Gardiner,et al.  Characterization of prostanoid relaxant/inhibitory receptors (ψ) using a highly selective agonist, TR4979 , 1986, British journal of pharmacology.

[102]  R. Mertelsmann,et al.  Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. , 1985, Journal of immunology.

[103]  R. Maca.  The effects of prostaglandins on the proliferation of cultured human T lymphocytes. , 1983, Immunopharmacology.

[104]  J. Ceuppens,et al.  Regulation of the immune response by prostaglandins , 1983, Journal of Clinical Immunology.

[105]  J. Murray,et al.  Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma , 1983, Journal of Clinical Immunology.

[106]  F. Bettens,et al.  Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. , 1983, Journal of immunology.

[107]  S. Kaufmann,et al.  Regulatory Interactions Between Macrophages and T-Cell Subsets in Listeria monocytogenes-Specific T-Cell Activation , 1982, Infection and immunity.

[108]  I. Barasoain,et al.  Exogenous additions of prostaglandins variably alter the blastogenic response of B and T lymphocytes from different mice lymphoid organs. , 1982, Immunopharmacology.

[109]  C. Griscelli,et al.  Role of prostaglandin E2 in the induction of nonspecific T lymphocyte suppressor activity. , 1981, Journal of immunology.

[110]  M. Caton,et al.  Prostaglandins and thromboxanes. , 1979, Progress in medicinal chemistry.

[111]  J. W. Smith,et al.  Cyclic adenosine 3',5'-monophosphate in human lymphocytes. Alterations after phytohemagglutinin stimulation. , 1971, The Journal of clinical investigation.

[112]  J. W. Smith,et al.  Human lymphocytic metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. , 1971, The Journal of clinical investigation.

[113]  S. Narumiya,et al.  Prostaglandin E 2 , an Immunoactivator , 2010 .

[114]  P. Krause,et al.  Prostaglandin E 2 enhances T-cell proliferation by inducing the costimulatory molecules OX 40 L , CD 70 , and 4-1 BBL on dendritic cells , 2009 .

[115]  T. Mcclanahan,et al.  Prostaglandin E 2 regulates Th 17 cell diff erentiation and function through cyclic AMP and EP 2 / EP 4 receptor signaling , 2009 .

[116]  J. Dayer,et al.  Prostaglandin E 2 synergistically with interleukin-23 favors human Th 17 expansion , 2008 .

[117]  A. Aasen,et al.  Lipopolysaccharide attenuates mRNA levels of several adenylyl cyclase isoforms in vivo. , 2007, Biochimica et biophysica acta.

[118]  T. Zander,et al.  Prostaglandin E 2 Impairs CD 4 + T Cell Activation by Inhibition of lck : Implications in Hodgkin ’ s Lymphoma , 2006 .

[119]  國方 友紀,et al.  Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3 , 2005 .

[120]  R. Majeti,et al.  Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. , 2002, The Journal of clinical investigation.

[121]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[122]  D. Dewitt,et al.  Prostaglandin endoperoxide H synthases-1 and -2. , 1996, Advances in immunology.

[123]  K. Prévost,et al.  Prostaglandin E2 promotes the induction of anergy during T helper cell recognition of myelin basic protein. , 1995, Cellular immunology.

[124]  J. Frost,et al.  Regulation of the MAP kinase cascade. , 1994, Cellular & molecular biology research.

[125]  J. Ledbetter,et al.  Phosphatidyl inositol hydrolysis after CD3 binding in human peripheral blood T cells: inhibition by prostaglandin E2. , 1989, International journal of immunopharmacology.

[126]  L. Hokin.  Receptors and phosphoinositide-generated second messengers. , 1985, Annual review of biochemistry.

[127]  K. Hopper,et al.  Immunoregulation by macrophages. III. Prostaglandin E suppresses lymphocyte activation but not macrophage effector function during Salmonella enteritidis infection. , 1984, International journal of immunopharmacology.

[128]  K. Resch,et al.  Suppression of T lymphocyte proliferation during lymphoma growth in mice: role of PGE2-producing suppressor macrophages. , 1982, Immunobiology.

[129]  T. Grosser,et al.  PROSTANOIDS IN HEALTH AND DISEASE , 1979 .

[130]  B. Samuelsson.  Prostaglandins and Thromboxanes , 1977, NATO Advanced Study Institutes Series.